Disc Medicine, Inc. | TalkMarkets | Page 1
No data available
No data available

Latest Posts

About This Stock More About This Stock
Week In Review: Mabwell Out-Licenses Rare Disease Drug For $412.5 Million
Article By: ChinaBio® Today
Saturday, January 21, 2023 3:51 PM EDT
Mabwell Biosciences out-licensed global rights for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Mabwell will receive $10 million upfront, $402.5 million in milestones, plus single digit royalties on sales.
In this article: IRON Also: SDGR, ROSS, GNNSF

Latest Tweets for $IRON

No tweets yet!